Scientific Advisory Board
Prof. Dr. Jörg Breitkreutz
Full Professor and Director of the Institute of Pharmaceutics and Biopharmaceutics at the Heinrich-Heine-University in Düsseldorf, Germany, and president of the non-for-profit International Association of Pharmaceutical Technology (APV), is a long-standing expert in the field of drug formulations, orphan drug development and process analytical technologies.
Dr. Waleed Danho
A world-wide renowned peptide chemist (Ph.D. from the University of Aachen (RWTH), Aachen, Germany) used to serve as an adjunct professor at the University of Medicine and Dentistry of New Jersey, USA. He held the position of Distinguished Research Leader at Hoffmann-La Roche Inc. in Nutley, New Jersey. He is a long-standing expert in drug discovery of peptide-based drugs. He authored and co-authored over 250 scientific articles and 21 patents in the field of peptides, acts as reviewer for renowned scientific journals and received multiple scientific awards. He serves as a council member of the American Peptide Society and a board member of trustees of the Boulder Peptide Society.
Prof. Dr. med. Gereon R. Fink
Full Professor and Director of the Department of Neurology at the University Hospital Cologne and Director of the Institute of Neuroscience and Medicine, Cognitive Neuroscience (INM-3) at the Research Center Jülich. He is a member of the Council of the German Neurological Society (DGN) with clinical specialization on cognitive neurology and dementia, stroke and neurorehabilitation, and movement disorders. His scientific interests include stroke and neurohabilitation, movement disorders and deep brain stimulation, and non-invasive neuromodulation including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).
Prof. Dr. med. Oliver Peters
Full Professor at Charité Universitätsmedizin Berlin, is currently chief of the branch Geriatric Neuropsychiatry at the Department of Psychiatry and Psychotherapy, Charité - Campus Benjamin Franklin. He is head of the Memory Clinic and Dementia Prevention Center at Experimental Clinical Research Center (ECRC), Charité - Campus Berlin Buch. He is principal investigator at the German Center for Neurodegenerative Diseases (DZNE) and board member of the German Dementia Competence Network (KND e.V.). He is interested in the establishment of, and has extensively worked on, new biomarkers for early diagnosis of chronic neurodegenerative diseases. He has participated as Principal Investigator in numerous observational and interventional clinical trials.
Prof. Dr. Holger Stark
Full Professor of the Institute of Pharmaceutical and Medicinal Chemistry at the Heinrich Heine University Düsseldorf, is an expert in the field of Medicinal Chemistry (i.a. drug research for CNS drugs/neurotransmitters, dopamine receptor subtypes, NMDA receptors and lipid signaling) and co-inventor of Wakix®, the first histamine H3 receptor antagonist into market.
Prof. Dr. med. Inga Zerr
Full Professor at the Institute of Neurodegenerative Diseases and Director of the German Reference Centre for Prion Disease Surveillance at the Department of Neurology at Georg-August-University Göttingen. She is member of the German Neurological Society (DGN) and German Society for Liquor Diagnostics in Neurology (DGLN). Her main research interests include genomics-, proteomics- and interactomics-based scientific approaches to investigate molecular mechanisms and post-translational modifications underlying neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease as well as Creutzfeldt-Jakob Disease. One of her specific scientific interests in the field of neurodegenerative disorders are patients with rapidly progressive Alzheimer´s disease (rpAD).